Insider Transactions Reported by 12 Insiders of Lexaria Bioscience Corp.

Symbol: LEXX on Nasdaq
Location: Kelowna, British Columbia, Canada

Key facts

LEXX - Lexaria Bioscience Corp. has 12 insiders with reported activity on this page.
Net insider value flow over the last year: +$49,085.
Recent transaction rows are available for direct filing-level review.

Change

Buy value: $49,085; sell value: $0.
Net share flow: +53,626.

Research use

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$49,085.

Buys

$49,085

Shares: 53,626

Insiders: 5

Sells

Shares: 0

Insiders: 0

Net

+$49,085

Shares: +53,626

Insiders: 5

Window (months)	Buy shares	Buy $	Sell $	Net $
0-3	0	$0	$0	$0
3-6	0	$0	$0	$0
6-9	0	$0	$0	$0
9-12	53,626	$49,085	$0	+$49,085

Lexaria Bioscience Corp. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Christopher Bunka	Director	$533,006	+$25,241	+5%	Mixed	17 Mar 2026
Richard Christopher	Chief Executive Officer, Director	$363,611	+$13,641	+3.9%	Mixed	29 Jul 2025
John Martin Docherty	President & CSO, Director	$322,458	+$4,989	+1.6%	Mixed	29 Jul 2025
Michael Elliot Shankman	Chief Financial Officer	$122,000			Mixed	15 May 2025
Nicholas W. Baxter	Director	$90,280			Mixed	15 May 2025
William Edward McKechnie	Director	$71,296	+$4,532	+6.8%	Mixed	29 Jul 2025
Vanessa Carle	Secretary	$65,932	+$683	+1%	Mixed	29 Jul 2025
Albert L. Reese Jr.	Director	$65,778			Mixed	15 May 2025
Baljinder Bhullar	Director	$15,860			Mixed	15 May 2025
Catherine C. Turkel	Director	$9,703			Filing P/S	12 Aug 2024
Gregory Downey	Chief Financial Officer	$4,084			Filing P/S	14 Oct 2022
Nelson Cabatuan	Chief Financial Officer				Mixed	14 Mar 2024

Top shareholders of Lexaria Bioscience Corp. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Christopher Bunka	3/4/5	Director	— mixed-class rows	740,289 mixed-class rows	$533,006	+$25,241	17 Mar 2026	3/4/5
Richard Christopher	3/4/5	Chief Executive Officer, Director	— mixed-class rows	415,000 mixed-class rows	$363,611	+$13,641	29 Jul 2025	3/4/5
Invenomic Capital Management LP	13F	Company	— class O/S missing	442,301	$344,995	—	31 Mar 2026	13F
John Martin Docherty	3/4/5	President & CSO, Director	— mixed-class rows	370,285 mixed-class rows	$322,458	+$4,989	29 Jul 2025	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	— class O/S missing	294,157	$229,471	—	31 Mar 2026	13F
VANGUARD CAPITAL MANAGEMENT LLC	13F	Company	— class O/S missing	222,293	$173,389	—	31 Mar 2026	13F
Michael Elliot Shankman	3/4/5	Chief Financial Officer	— class O/S missing	100,000	$122,000	—	15 May 2025	3/4/5
TORONTO DOMINION BANK	13F	Company	— class O/S missing	140,013	$109,279	—	31 Mar 2026	13F
Nicholas W. Baxter	3/4/5	Director	— mixed-class rows	74,000 mixed-class rows	$90,280	—	15 May 2025	3/4/5
VANGUARD FIDUCIARY TRUST CO	13F	Company	— class O/S missing	94,166	$73,449	—	31 Mar 2026	13F
William Edward McKechnie	3/4/5	Director	— mixed-class rows	81,191 mixed-class rows	$71,296	+$4,532	29 Jul 2025	3/4/5
Vanessa Carle	3/4/5	Secretary	— mixed-class rows	75,817 mixed-class rows	$65,932	+$683	29 Jul 2025	3/4/5
Albert L. Reese Jr.	3/4/5	Director	— mixed-class rows	53,917 mixed-class rows	$65,778	—	15 May 2025	3/4/5
UBS Group AG	13F	Company	— class O/S missing	52,708	$41,112	—	31 Mar 2026	13F
STATE STREET CORP	13F	Company	— class O/S missing	39,301	$30,655	—	31 Mar 2026	13F
BlackRock, Inc.	13F	Company	— class O/S missing	27,445	$21,407	—	31 Mar 2026	13F
XTX Topco Ltd	13F	Company	— class O/S missing	25,067	$19,552	—	31 Mar 2026	13F
Krilogy Financial LLC	13F	Company	— class O/S missing	19,653	$19,358	—	31 Mar 2026	13F
Vontobel Holding Ltd.	13F	Company	— class O/S missing	23,000	$17,940	—	31 Mar 2026	13F
Baljinder Bhullar	3/4/5	Director	— mixed-class rows	24,000 mixed-class rows	$15,860	—	15 May 2025	3/4/5
NORTHERN TRUST CORP	13F	Company	— class O/S missing	18,389	$14,343	—	31 Mar 2026	13F
HRT FINANCIAL LP	13F	Company	— class O/S missing	18,465	$14,000	—	31 Mar 2026	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	— class O/S missing	16,300	$12,714	—	31 Mar 2026	13F
BANK OF MONTREAL /CAN/	13F	Company	— class O/S missing	14,033	$10,946	—	31 Mar 2026	13F
CITADEL ADVISORS LLC	13F	Company	— class O/S missing	13,513	$10,540	—	31 Mar 2026	13F
Catherine C. Turkel	3/4/5	Director	— mixed-class rows	45,100 mixed-class rows	$9,703	—	12 Aug 2024	3/4/5
Vanguard Global Advisers, LLC	13F	Company	— class O/S missing	10,204	$7,959	—	31 Mar 2026	13F
BCV Asset Management Inc.	13F	Company	— class O/S missing	10,000	$7,800	—	31 Mar 2026	13F
ROYAL BANK OF CANADA	13F	Company	— class O/S missing	7,140	$6,000	—	31 Mar 2026	13F
Gregory Downey	3/4/5	Chief Financial Officer	— mixed-class rows	47,954 mixed-class rows	$4,084	—	14 Oct 2022	3/4/5
Byrne Asset Management LLC	13F	Company	— class O/S missing	800	$624	—	31 Mar 2026	13F
OSAIC HOLDINGS, INC.	13F	Company	— class O/S missing	605	$471	—	31 Mar 2026	13F
CITIGROUP INC	13F	Company	— class O/S missing	489	$381	—	31 Mar 2026	13F
Federation Des Caisses Desjardins du Quebec	13F	Individual	— class O/S missing	382	$298	—	31 Mar 2026	13F
Farther Finance Advisors, LLC	13F	Company	— class O/S missing	166	$144	—	31 Mar 2026	13F
GABLES CAPITAL MANAGEMENT INC.	13F	Company	— class O/S missing	13	$10	—	31 Mar 2026	13F
MORGAN STANLEY	13F	Company	— class O/S missing	3	$2	—	31 Mar 2026	13F
Tower Research Capital LLC (TRC)	13F	Company	— class O/S missing	2	$2	—	31 Mar 2026	13F
SBI Securities Co., Ltd.	13F	Company	— class O/S missing	1	$1	—	31 Mar 2026	13F

Recent Insider Transactions by Companies or Individuals for Lexaria Bioscience Corp.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Christopher Bunka	LEXX	common shares	Gift	-26.8%			-100,000	273,543	17 Mar 2026	Direct
Christopher Bunka	LEXX	common shares	Purchase	4.41%	$10,866	$0.9131	11,900	281,912	30 Jul 2025	Private Holding Company
Christopher Bunka	LEXX	common shares	Purchase	6.13%	$14,375	$0.9215	15,600	270,012	29 Jul 2025	Private Holding Company
William Edward McKechnie	LEXX	common shares	Purchase	37.9%	$4,532	$0.9063	5,000	18,191	29 Jul 2025	Direct
John Martin Docherty	LEXX	common shares	Purchase		$4,989	$0.9280	5,376	5,376	29 Jul 2025	Direct
Vanessa Carle	LEXX	common shares	Purchase		$682	$0.9100	750	750	29 Jul 2025	Direct
Richard Christopher	LEXX	common shares	Purchase	30%	$13,641	$0.9094	15,000	65,000	29 Jul 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.